COL18A1 antibody (Chain alpha 1)

Catalog No. ABIN1106765

Product Details anti-COL18A1 Antibody

Target: COL18A1 (Collagen, Type XVIII, alpha 1 (COL18A1))

Binding Specificity: Chain alpha 1

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This COL18A1 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA)

Specificity: Monoclonal antibody 1837-46 reacts with endostatin, a 20 kDa C-terminal fragment of collagen XVIII.

Cross-Reactivity (Details): Species reactivity (tested):Human

Purification: Protein G

Clone: 1837-46

Isotype: IgG2b

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.1 mg/mL

Buffer: PBS, 0.02 % sodium azide, 0.1 % bovine serum albumin

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Prior to reconstitution store at 2-8 °C. Following reconstitution store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Target Details for COL18A1

Target: COL18A1 (Collagen, Type XVIII, alpha 1 (COL18A1))

Abstract: COL18A1 Products

Synonyms: KNO antibody, KNO1 antibody, KS antibody, cb371 antibody, cb529 antibody, fc96d06 antibody, sb:cb529 antibody, wu:fb47h10 antibody, wu:fb77g12 antibody, wu:fc50f04 antibody, wu:fc96d06 antibody, wu:fk02h12 antibody, kno antibody, kno1 antibody, collagen type XVIII alpha 1 chain antibody, collagen type XVIII alpha 1 chain a antibody, collagen, type XVIII, alpha 1 antibody, collagen type XVIII alpha 1 antibody, COL18A1 antibody, col18a1a antibody, Col18a1 antibody, col18a1 antibody

Background: Endostatin is able to evoke non-uniform response for proliferation, cell mount and migration of entothelial cells, with different endostatin binding characteristic, leads to the assumption that endostatin effect is strongly dependent from endothelial cell type. Furthermore endostatin inhibits angiogenesis and tumor growth in vivo by inducing apoptosis in endothelial cells. The local delivery of endostatin seems to specifically affect tumor-associated microvessels by reduction of the vessel density, diameter and functionality. Tumor cell migration and invasion was greatly reduced in the endostatin treated animals. Endostatin is non-toxic and does not induce acquired drug resistance and has therefore become a potent new therapy strategy in solid neoplasias. This therapy appear to have high potential not only for the treatment of gliomas, the most common brain tumours, but also of other tumours. The ability of endostatin to inhibit neoangiogenesis is mediated, at least in part, by Zn2+ binding and elastase processing. Widespread endostatin expression was found in elastic fibers in vessel walls and in some other basement membrane zones. Endostatin is released by neurons to accumulate in amyloid plaques in Alzheimer's disease.Synonyms: COL18A1, Endostatin, KNO1

Gene ID: 80781

NCBI Accession: NP_085059

UniProt: P39060